Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape should ultimately lead to more subset-specific AML therapies, ideally tailored to each patient's disease. Although a growing number of distinct AML subsets have been increasingly characterized, patient management has remained disappointingly uniform. If one excludes acute promyelocytic leukemia, current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least in younger patients who can tolerate such intensive treatments. Nevertheless, progress has been made, notably in terms of standard drug dose intensification and safer allogeneic HSCT procedures, allowing a larger proportion of patients to achieve durable remission. In addition, improved identification of patients at relatively low risk of relapse should limit their undue exposure to the risks of HSCT in first remission. The role of new effective agents, such as purine analogs or gemtuzumab ozogamicin, is still under investigation, while promising new targeted agents are under clinical development. In contrast, minimal advances have been made for patients unable to tolerate intensive treatment, mostly representing older patients. The availability of hypomethylating agents likely represents an encouraging first step for this latter population, and will hopefully allow for more efficient combinations with novel agents.
Introduction
Long-term cure of patients with acute promyelocytic leukemia (APL) using retinoic acid and arsenic trioxide (ATO) therapy represents the only dramatic therapeutic advance over the last two decades in acute myeloid leukemia (AML). 1 Although increasingly refined knowledge of AML biology has led to the development of new targeted agents such as the mutated FLT3 or IDH inhibitors, current advances in non-APL patients lack innovation, relying instead on modifications to doses and schedules of standard cytotoxic drugs or progress in hematopoietic stem cell transplantation (HSCT) techniques. In younger patients, complete remission (CR)
rates of 80% or more may be reached, with 5-year overall survival (OS) around 40%.
In older patients, the use of hypomethylating agents has improved median and shortterm OS but has not translated into improved cure rates, which remain disappointingly very low. Guidelines for AML management are widely available. This review aims to provide a balanced perspective of available data supporting AML treatment used in routine practice today. We have focused on data from randomized clinical trials using approved drugs. Early results with new investigational drugs will be discussed in depth in another article of this Review Series.
Front-line induction therapy
Induction therapy with cytarabine and an anthracycline remains a standard of care in AML. The standard combination is the 7+3, with a 7-day continuous infusion of cytarabine at the dosage of 100 or 200 mg/m 2 /day, days 1 to 7 and daunorubicin at Acute Leukemia Study Group (JALSG) AML201 study which compared two courses of 50 mg/m 2 daunorubicin for 5 days with 12 mg/m 2 idarubicin for 3 days. Anti-leukemic activity of 60 and 90 mg/m 2 daunorubicin or 12 mg/m 2 idarubicin daily doses thus appears to be similar, as are the toxicity profiles, at least in cases when a second anthracycline-containing cycle is not given systematically to responders.
Cytarabine
Randomized studies exploring cytarabine dose and schedule during induction are summarized in Table 2 . Historical studies from the Southwest Oncology Group Similar rates of CR, event-free survival (EFS), and OS were observed in the two arms, with more toxicity associated with the HiDAC arm.
In the second study, conducted by the EORTC and GIMEMA Leukemia Groups, patients were randomized to receive either standard doses at 100 mg/m 2 /day cytarabine for 10 days or HiDAC at 3,000 mg/m 2 /12h on day 1, 3, 5, and 7 during the first course. 13 A higher CR rate was observed in the HiDAC arm, with a trend for a longer OS that reached statistical significance in the subset of patients aged 45 years and younger. Finally, in the randomized German Intergroup study that included
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14 It thus remains unclear if increasing the cytarabine dose during induction may benefit patients planned to receive IDAC or HiDAC during post-remission therapy.
"Dose-dense" regimens
Another approach to increasing induction intensity relies on systematic administration of a second sequence of chemotherapy starting earlier than normal after the completion of the first sequence (generally between day 7 and day 14). This timed-sequential concept was initially developed by the John Hopkins group in Baltimore, 15 then prospectively evaluated by the ALFA group without incorporating HiDAC. 16 After investigating double induction containing one or two HiDAC sequences (TAD-HAM or HAM-HAM), 17 the German AML Cooperative Group (AMLCG) recently conducted a phase 2 trial investigating a sequential S-HAM. 18 However, none of these studies provide evidence that a dose-dense regimen is superior to the standard 7+3 regimen, especially when high doses of daunorubicin are used.
Addition of a third drug

Gemtuzumab ozogamicin (GO)
Randomized studies exploring the addition of GO to intensive chemotherapy (ICT) are summarized in Table 3 . Six studies evaluating the addition of 3 or 6 mg/m² GO during induction have been performed. [19] [20] [21] [22] [23] [24] The first of them, SWOG S0106, was negative and closed prematurely due to a higher early mortality rate despite a reduced 45 mg/m 2 /day daunorubicin dose in the GO arm, leading to GO withdrawal by the Food and Drug Administration in the United States. 19 Conversely, four studies reported significant improvements when GO was combined with induction or induction and consolidation chemotherapy. [20] [21] [22] [23] This finding was confirmed in a
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From recent meta-analysis. 25 Nonetheless, the addition of GO was associated with more frequent severe liver toxicity and persistent thrombocytopenia. The benefit/risk ratio appeared to be at least as good with 3 mg/m 2 per dosing, 24 a dose that can be administered to older patients, 21 and ultimately be repeated as successfully developed by the ALFA group. 22 In contrast, increased toxicity and an absence of clinical benefit were observed in the EORTC/GIMEMA study, in which single-agent GO administration preceded induction chemotherapy. 26 Finally, the two studies that evaluated GO maintenance therapy were negative. 19 
Purine analogs
Randomized studies exploring the addition of purine analogs to ICT are summarized in 
Post-remission therapy
HiDAC consolidation
For younger patients not undergoing HSCT, administration of several HiDAC consolidation courses using cytarabine twice daily at 3 g/m 2 /dose on day 1, 3 and 5 has been a widely used option since 1994. 36 Even if the optimal cytarabine dose, schedule of administration and number of cycles need yet to be defined, 37, 38 
Allogeneic HSCT
One of the most important treatment decisions in AML is to estimate the benefit/risk associated with allogeneic HSCT in first remission for a given patient.
Transplantation offers the best means of preventing AML recurrence, but remains associated with higher treatment-related morbidity and mortality (TRM), especially in older patients. In patients with favorable-risk AML, the relapse risk may be low enough and the salvage rate high enough to postpone HSCT to second remission.
This strategy has been validated in several donor versus no-donor studies. 40 Reliance on genetic profiles as the main treatment-stratifying tool is being increasingly challenged due to multiple recently described genetic mutations and the 
Targeted treatments for specific AML subgroups
Core binding factor AML
A subgroup analysis of the MRC AML15 younger population AML trial along with a subsequent meta-analysis, 20 ,25 strongly suggest that the combination of GO with ICT is associated with a significant OS benefit in CBF-AML, renewing interest in this drug, which is currently unavailable outside the context of clinical studies, for this AML subset.
Frequent KIT mutations or overexpression of the KIT receptor were described some time ago in CBF-AML. Recent studies have evaluated the potential benefit of dasatinib, a potent KIT inhibitor, in these patients. In a French study, patients with persistent MRD or molecular relapse after intensive consolidations were eligible to receive 12 months maintenance with dasatinib if they were not candidate for HSCT. 59 No significant impact of dasatinib on time-to-relapse was seen. Two phase 1-2 trials combined dasatinib with upfront ICT led to a currently ongoing phase 3 trial.
60,61
AML with FLT3 gene mutation
The FLT3-ITD mutation is one of the most frequent bad-prognosis mutations observed in AML, at least in younger or relapsed patients and has led to the evaluation of multikinase or more specific kinase inhibitors in this AML subset. 
AML with mutated IDH
Isocitrate dehydrogenase 1 and 2 gene mutations are present in 10 to 15% of AML patients. As detailed in another article of this Review Series, early phase 1/2 results of specific inhibition of IDH2 and IDH1 mutated enzymes are impressive. A phase 3 study will soon be initiated in relapsing IDH2 mutated patients.
AML with adverse cytogenetic features
In this hard-to-treat AML population, improvement of early response rate remains an important clinical endpoint, especially when HSCT can be envisioned in a timely manner. However, results of trials with novel drugs are disappointing. In the PALG cladribine study, 28 the subgroup of patients with unfavorable cytogenetics appeared, nevertheless, to have a greater benefit. Similarly, a combination of cladribine, cytarabine, priming with G-CSF, and mitoxantrone (CLAG-M) was reported to be of benefit compared to 7+3 in a large retrospective single center study which mostly 
Treatment of older AML
Outcome in older patients with AML remains dismal, with lower CR rates and very The most important clinical decision remains to estimate the benefit/risk associated with ICT in the individual older patient. As for the decision to recommend HSCT in first CR, there is no unique decision-guiding score. Older patients with favorable-risk AML according to ELN classification are likely to benefit from a standard treatment. 75, 76 In those unlikely to benefit from ICT, low-dose cytarabine (LDAC) has been considered as a possible standard, based on the non-intensive AML14 MRC trial results, despite the fact that patients with adverse cytogenetics did not draw any benefit from LDAC therapy. 77 In two large international trials, the hypomethylating agents decitabine and azacitidine yielded better mid-term results, with longer median and higher 1-year survival than observed in LDAC arms, even if they did not result in vosaroxin with decitabine in a single-center evaluation. 87 Too frequently, the evaluation of the efficacy of the combinations is hindered by their poor tolerance in older patients deemed unfit for standard ICT, raising the issue of their evaluation in fitter patients, potentially against ICT.
Treatment of relapsed/refractory AML
Treatment of relapsed AML remains poorly defined. Simple clinical and disease parameters such as age, duration of first remission, cytogenetics, and prior HSCT remain the most useful parameters to evaluate treatment effects at relapse. 88 In most AML subsets (other than APL) the main clinical objective of salvage therapy is to "bridge" patients to HSCT, either with targeted therapies such as FLT3 inhibitors or with ICT, at least in patients fit enough to tolerate it. A very large cohort of relapsed AML patients subjected to salvage therapy after being treated frontline in successive MRC AML trials has recently been described. 89 are unclear at best. Recently, two large company-sponsored studies evaluated the combination of clofarabine or vosaroxin to IDAC, with OS as the endpoint in R/R AML patients. In the CLASSIC I trial, addition of clofarabine increased the response rate in patients more than 55 years of age, albeit at the expense of increased toxicity and early mortality, but failed to improve OS despite a higher number of patients bridged to HSCT. 90 In the preliminary results of the largest trial ever performed in R/R patients, the VALOR trial, combination of vosaroxin to IDAC similarly increased the response rate across all ages in both relapsed and refractory patients.
Nonetheless, despite the absence of a significant increase in early mortality and a large proportion of younger patients bridged to HSCT, this did not translate into a general OS improvement. A significant, although modest, survival improvement was only observed in older patients aged 60 years or more.
91
Conclusion
In conclusion, despite some advances in the treatment of adult AML patients, many issues remain to be addressed, as reflected by current recommendations. given to patients with persistent leukemia after cycle1; *** in this study, all patients but poor-risk received a second DA course with 50 mg/m 2 /d daunorubicin; **** A second cycle, identical to the first one, was given to patients with persistent leukemia after cycle 1; † A significant EFS and OS benefit was observed in the subgroup of patients aged 60-65 y.
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